search
Back to results

Corever in the Treatment of Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
Corever
Sponsored by
TSH Biopharm Corporation Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Corever, hypertension

Eligibility Criteria

20 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients who are 20-90 years of age
  2. Patients who belong to either one of the following categories:

    With essential hypertension, as measured by office BP and are not on antihypertensive treatment at screening .

    With uncontrolled hypertension despite treatment with up to 2 antihypertensive agents, and the type and dose of the agents shall be maintained for at least 28 days prior to entering this trial.

  3. Agree to and are able to follow the study procedures.
  4. Understand the nature of the study, and have signed informed consent forms.

Exclusion Criteria:

  1. Patients with any of the following conditions:

    • Malignant hypertension
    • Secondary hypertension
    • Average sitting SBP ≥ 180 mmHg
    • Advanced hypertensive retinopathy
    • Type 1 diabetes
    • Acute coronary syndrome
    • Clinical significant valvular disease
    • Hypertrophic cardiomyopathies
    • New York Heart Association class III -IV congestive HF
    • Second or third degree atrioventricular block or history of sick sinus syndrome unless a pacemaker is in place
    • Atrial fibrillation
    • Sinus bradycardia (<60 bpm)
    • Asthma
    • Stroke within 3 months
    • Cancer with expected survival less than 3 years
    • A difference of > 20 mmHg for SBP or > 10 mmHg for DBP between arms at screening
    • Severe hepatic impairment
    • A history of a serious hypersensitivity reaction.
  2. Patients with clinically significant abnormalities.
  3. Patients with known contraindication to Corever.
  4. Female patients who are pregnant or lactating.
  5. 5. Male or female patients of child-bearing potential who do not agree to use an effective method of contraception during the study.
  6. Patients is currently participating in any other clinical trial within 30 days
  7. Patients need to be treated with the permitted medication.

Sites / Locations

  • Hualien Tzu Chi Hospital
  • Kaohsiung Chang Gung Memorial Hospital
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Chung Shan Medical University Hospital
  • Taichung Veterans General Hospital
  • National Taiwan University Hospital
  • Shin Kong Wu Ho-Su Memorial Hospital
  • Taipei Veterans General Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Placebo Comparator

Placebo Comparator

Arm Label

Corever middle dose

Corever high dose

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Seated Office SBP reduction (SBP each visit-SBP visit 2)
To compare the change in office SBP measurements by cuff assessments after 8 weeks of treatment

Secondary Outcome Measures

Seated Office DBP reduction (DBP each visit-DBP visit 2)
To compare the change in office DBP measurements by cuff assessments after 8 weeks of treatment To compare the percentage of subjects who achieve BP goal as measured by cuff assessments (140/90 mmHg) after 8 weeks of treatment

Full Information

First Posted
January 29, 2015
Last Updated
November 2, 2016
Sponsor
TSH Biopharm Corporation Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT02432937
Brief Title
Corever in the Treatment of Hypertension
Official Title
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study of Corever for the Treatment of Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
August 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TSH Biopharm Corporation Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study primarily aims to compare the effects of two doses of Corever with placebo in patients with hypertension.
Detailed Description
The study aims to compare the effects of two doses of Corever with placebo in patients with essential hypertension. Eligible subjects who belong to one of the following subtypes are planned to be enrolled: (1) patients with essential hypertension without drug control, or (2) uncontrolled hypertension despite treatment with up to 2 antihypertensive agents. Of note, the second category will receive randomized study treatments in addition to continuing their previous medication throughout the trial. The study also wants to investigate the safety profile of Corever during treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Corever, hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
134 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Corever middle dose
Arm Type
Placebo Comparator
Arm Title
Corever high dose
Arm Type
Placebo Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Corever
Other Intervention Name(s)
CRTA04
Intervention Description
Corever
Primary Outcome Measure Information:
Title
Seated Office SBP reduction (SBP each visit-SBP visit 2)
Description
To compare the change in office SBP measurements by cuff assessments after 8 weeks of treatment
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Seated Office DBP reduction (DBP each visit-DBP visit 2)
Description
To compare the change in office DBP measurements by cuff assessments after 8 weeks of treatment To compare the percentage of subjects who achieve BP goal as measured by cuff assessments (140/90 mmHg) after 8 weeks of treatment
Time Frame
8 weeks
Other Pre-specified Outcome Measures:
Title
Safety-Adverse events
Time Frame
8 weeks
Title
Safety-Changes in vital signs
Time Frame
8 weeks
Title
Safety-Changes in laboratory examinations
Time Frame
8 weeks
Title
Safety-Changes in electrocardiograms
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who are 20-90 years of age Patients who belong to either one of the following categories: With essential hypertension, as measured by office BP and are not on antihypertensive treatment at screening . With uncontrolled hypertension despite treatment with up to 2 antihypertensive agents, and the type and dose of the agents shall be maintained for at least 28 days prior to entering this trial. Agree to and are able to follow the study procedures. Understand the nature of the study, and have signed informed consent forms. Exclusion Criteria: Patients with any of the following conditions: Malignant hypertension Secondary hypertension Average sitting SBP ≥ 180 mmHg Advanced hypertensive retinopathy Type 1 diabetes Acute coronary syndrome Clinical significant valvular disease Hypertrophic cardiomyopathies New York Heart Association class III -IV congestive HF Second or third degree atrioventricular block or history of sick sinus syndrome unless a pacemaker is in place Atrial fibrillation Sinus bradycardia (<60 bpm) Asthma Stroke within 3 months Cancer with expected survival less than 3 years A difference of > 20 mmHg for SBP or > 10 mmHg for DBP between arms at screening Severe hepatic impairment A history of a serious hypersensitivity reaction. Patients with clinically significant abnormalities. Patients with known contraindication to Corever. Female patients who are pregnant or lactating. 5. Male or female patients of child-bearing potential who do not agree to use an effective method of contraception during the study. Patients is currently participating in any other clinical trial within 30 days Patients need to be treated with the permitted medication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chern-En Chiang, M.D., Ph.D.,
Organizational Affiliation
Taipei Veterans General Hospital, Taiwan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hualien Tzu Chi Hospital
City
Hualien
Country
Taiwan
Facility Name
Kaohsiung Chang Gung Memorial Hospital
City
Kaohsiung
Country
Taiwan
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital
City
Kaohsiung
Country
Taiwan
Facility Name
Chung Shan Medical University Hospital
City
Taichung
Country
Taiwan
Facility Name
Taichung Veterans General Hospital
City
Taichung
Country
Taiwan
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Facility Name
Shin Kong Wu Ho-Su Memorial Hospital
City
Taipei
Country
Taiwan
Facility Name
Taipei Veterans General Hospital
City
Taipei
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Corever in the Treatment of Hypertension

We'll reach out to this number within 24 hrs